Gout biotech CymaBay Therapeutics files for a $30 million IPO
CymaBay Therapeutics, a clinical-stage biotech developing treatments for gout and other metabolic and rare diseases, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering. The Newark, CA-based company, which was founded in 1988, plans to list on the NASDAQ under the symbol CBAY. Cowen & Company and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.